BUZZ-Orexigen Therapeutics Inc: Up after signing deal with Valeant
** Drugmaker's shares up 12 pct at $4.3 premarket
** Signs deal with Valeant Pharmaceuticals International Inc for its weight loss drug, Contrave
** Valeant will be responsible for obtaining Canadian regulatory approval, commercialization activity and expenses for the drug
** Orexigen expects Valeant to file with Health Canada for regulatory approval by January
** Contrave was approved by U.S. FDA in 2014
** Up to Monday's close, stock had fallen 86.2 pct YTD
© Thomson Reuters 2017 All rights reserved.